Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEvogene

Evogene

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.2875 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
130285
Market Cap
8.34M

Momentum Score

…

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.27
Low
0.30
High
52 Week Price Range
0.37
Low
1.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Evogene is an Israeli computational biology company that applies machine learning and proprietary discovery platforms to identify and develop crop traits, biologicals and other life-science candidates. Major long-term growth drivers include wider adoption of AI-enabled discovery, progression and commercialization of its pipeline through partnerships and licensing, and the scalability of platform-based research. Investors may find the company attractive because a platform approach could support multiple product candidates and potential recurring licensing revenue if those candidates advance.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.29
Dividend Yield
-
Revenue TTM
1.66M
Revenue Per Share
0.17
Gross Profit TTM
-1.12M
Debt / Equity
-26.80
ROE
-182.75%
Net Debt
-10.76M
ROCE
-80.36%
Diluted EPS TTM
-1.75

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -13.50M -14.81M -25.99M -29.75M -30.43M
Minority interest -0.66M 1.57M 2.16M 3.21M 2.65M
Net income -8.48M -16.48M -23.88M -29.84M -30.45M
Selling general administrative 5.58M 8.75M 8.67M 6.48M 7.25M
Selling and marketing expenses 0.18M 0.22M 1.01M 3.93M 0.65M
Gross profit -0.24M 3.20M 1.40M 0.77M 0.16M
Reconciled depreciation 1.14M 2.50M 2.59M 2.58M 2.23M
Ebit -13.34M -14.74M -26.39M -26.94M -30.95M
Ebitda -12.20M -13.36M -23.78M -23.84M -26.78M
Depreciation and amortization 1.14M 1.38M 2.61M 3.10M 4.17M
Operating income -14.03M -18.80M -26.39M -26.94M -30.95M
Other operating expenses 17.89M 24.38M 32.03M 28.62M 31.88M
Interest expense 1.89M 0.12M 0.12M 3.33M 1.41M
Tax provision 0.00M 0.01M 0.02M 0.09M 0.01M
Interest income 0.36M 0.96M 0.63M 0.52M 1.94M
Net interest income -1.28M 0.41M 2.82M -2.81M 0.52M
Income tax expense 0.00M 0.01M -0.03M 0.09M 0.01M
Total revenue 3.85M 5.58M 5.64M 1.68M 0.93M
Total operating expenses 13.79M 22.00M 27.79M 27.71M 31.12M
Cost of revenue 4.09M 2.38M 4.24M 0.91M 0.77M
Total other income expense net 0.54M 4.00M 0.40M -2.81M 0.52M
Net income from continuing ops -13.50M -18.05M -22.44M -29.84M -30.45M
Net income applicable to common shares - - - -26.64M -27.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 20.05M 39.86M 51.10M 56.13M 76.30M
Intangible assets - 12.20M 13.17M 14.14M 15.21M
Other current assets 1.09M 2.97M 1.04M 0.03M 2.03M
Total liab 8.07M 25.03M 17.99M 21.34M 12.88M
Total stockholder equity -0.08M -1.45M 12.05M 27.93M 54.03M
Other current liab 2.02M 5.82M 3.94M 3.60M 4.18M
Common stock 0.49M 0.36M 0.29M 0.23M 0.23M
Capital stock 0.49M 0.36M 0.29M 0.23M 0.23M
Retained earnings -282.56M -274.07M -257.59M -233.71M -207.07M
Other liab - - - 14.78M 4.31M
Other assets - - 0.00M 0.17M 0.03M
Cash 12.96M 15.30M 20.77M 28.98M 32.33M
Total current liabilities 3.44M 18.70M 6.94M 5.62M 6.88M
Current deferred revenue 0.07M 0.68M 0.36M 0.10M 0.26M
Net debt -10.76M -2.43M -19.63M -17.05M -29.66M
Short term debt 0.72M 10.96M 0.85M 0.88M 0.97M
Short long term debt - 10.37M - - -
Short long term debt total 2.20M 12.87M 1.14M 11.93M 2.67M
Other stockholder equity 281.99M 272.26M 269.35M 261.40M 260.87M
Property plant equipment - - - 4.07M 4.18M
Total current assets 15.63M 21.59M 34.47M 37.75M 56.89M
Long term investments 0.04M 0.08M - - -
Net tangible assets - - - 13.79M 38.82M
Short term investments 0.03M 0.01M 10.29M 6.38M 21.54M
Net receivables 1.38M 1.49M 0.67M 1.83M 2.93M
Long term debt - - 10.37M 10.11M -
Inventory 0.21M 1.82M 1.69M 0.57M 0.09M
Accounts payable 0.64M 1.23M 1.78M 1.04M 1.46M
Accumulated other comprehensive income 281.99M 272.26M 269.35M - -
Non currrent assets other 1.74M 1.75M 0.03M 0.07M 0.03M
Non current assets total 4.42M 18.27M 16.63M 18.38M 19.41M
Capital lease obligations 2.20M 2.50M 1.14M 1.82M 2.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.00M 9.62M -4.40M 13.27M -19.72M
Change to liabilities - - - -0.72M 0.75M
Total cashflows from investing activities 17.74M 9.62M - 13.27M -20.44M
Net borrowings -0.53M -0.90M - -0.80M -0.58M
Total cash from financing activities -6.60M 4.66M 18.15M 9.34M 30.28M
Change to operating activities - - - 0.49M 1.05M
Net income -14.16M -18.05M -23.88M -29.84M -30.45M
Change in cash -2.35M -5.47M -8.24M -3.35M -13.90M
Begin period cash flow 15.30M 20.77M 29.01M 32.33M 46.23M
End period cash flow 12.96M 15.30M 20.77M 28.98M 32.33M
Total cash from operating activities -13.50M -19.70M -21.58M -23.68M -24.84M
Issuance of capital stock 4.28M 0.12M 8.43M 0.02M 29.58M
Depreciation 1.14M 2.50M 2.61M 2.58M 2.23M
Other cashflows from investing activities 17.80M 0.06M - - -
Change to inventory -1.02M -1.74M 0.49M -0.47M -0.09M
Change to account receivables 1.71M 0.19M -1.45M -0.07M -0.06M
Other cashflows from financing activities -10.36M 5.43M 10.54M 10.12M 1.27M
Change to netincome - - - 1.15M -0.94M
Capital expenditures 0.14M 0.63M 0.79M 1.17M 0.72M
Change in working capital -1.25M -3.31M -0.40M -0.77M 1.66M
Stock based compensation 0.65M 1.79M 1.88M 1.19M 2.61M
Other non cash items 0.12M -2.64M -1.75M 3.08M -0.91M
Free cash flow -13.64M -20.33M -22.36M -24.85M -25.56M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EVGN
Evogene		 -
-%		 0.29 - - 5.04 4.71 0.18 -0.81
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

13 Gad Feinstein Street, Rehovot, Israel, 7638517

972 8 931 1900

https://www.evogene.com

38

Name Title Year Born
Mr. Ofer Haviv CPA CEO & Pres 1966
Mr. Mark Kapel Chief Technology Officer 1977
Dr. Elran Hillel Haber M.B.A., Ph.D. Chief Exec. Officer of Biomica Ltd 1980
Mr. Yaron Eldad Chief Financial Officer 1965
Dr. Eyal Emmanuel Chief Scientific Officer 1973
Mr. Sassi Masliah Exec. VP of Corp. Devel. 1979
Ms. Liat Foigel Wejgman VP of HR NA
Dr. Nir Arbel Chief Product Officer 1980
Mr. Dotan Borenstein Chief Bus. Officer of Lavie Bio Ltd. NA
Mr. Eyal Ronen Exec. VP of Bus. Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…